Por favor, use este identificador para citar o enlazar este ítem:
https://www.arca.fiocruz.br/handle/icict/51046
Tipo
ArtículoDerechos de autor
Acceso abierto
Colecciones
Metadatos
Mostrar el registro completo del ítem
RESVERATROL SUSCEPTIBILITY OF STREPTOCOCCUS PNEUMONIAE AND NEISSERIA MENINGITIDIS STRAINS ISOLATED IN THE STATE OF MINAS GERAIS, BRAZIL, FROM 2007 TO 2013
Neisseria meningitides
Resveratrol; 3,5,4’-trihydroxylstilbene
Bacterial meningitis
Antibacterials
Natural Compounds
Autor
Afiliación
Fundação Oswaldo Cruz. Centro de Pesquisas René Rachou. Neurogenomics. Belo Horizonte, MG, Brazil/ Estado de Minas Gerais. Fundação Ezequiel Dias. Service of Bacterial and Fungal Diseases. Belo Horizonte, MG, Brazil
Fundação Oswaldo Cruz. Centro de Pesquisas René Rachou. Functional Genomics and Proteomics of Leishmania ssp and Trypanosoma cruzi. Belo Horizonte, MG, Brazil
Estado de Minas Gerais. Fundação Ezequiel Dias. Service of Bacterial and Fungal Diseases. Belo Horizonte, MG, Brazil
Fundação Oswaldo Cruz. Centro de Pesquisas René Rachou. Neurogenomics. Belo Horizonte, MG, Brazil
Fundação Oswaldo Cruz. Centro de Pesquisas René Rachou. Functional Genomics and Proteomics of Leishmania ssp and Trypanosoma cruzi. Belo Horizonte, MG, Brazil
Estado de Minas Gerais. Fundação Ezequiel Dias. Service of Bacterial and Fungal Diseases. Belo Horizonte, MG, Brazil
Fundação Oswaldo Cruz. Centro de Pesquisas René Rachou. Neurogenomics. Belo Horizonte, MG, Brazil
Resumen en ingles
Objective: Evaluation of the in vitro susceptibility to Resveratrol of a bacterial collection representing the S. pneumoniae and N. meningitidis strains prevalent in the Brazilian state of Minas Gerais from 2007 to 2013.
Methods: One reference strain of S. pneumoniae (ATCC 49619), and sixty-three strains (31 S. pneumoniae, and 32 N. meningitidis) isolated from patients with meningitis and available at the certified strains collection of Ezequiel Dias Foundation were tested. The susceptibility to Resveratrol was tested on blood agar containing this drug at eight concentrations ranging from 25 mg/L to 200 mg/L diluted in 0.5% ethanol, and control plates with blood agar with 0.5% ethanol. Pneumococci were also tested for susceptibility to currently available antimicrobials used to treat meningitis using E-test and disc diffusion methods. The association between pneumococcal susceptibility to Resveratrol and to any other antibiotic tested was assessed with chi-square test, and the toxic doses of Resveratrol were determined upon L929 mammalian cells.
Results: The MIC100 for Resveratrol was 75 mg/L for meningococci (range: 50-75 mg/L), and 200 mg/L for pneumococci (range: 125-200 mg/L). There was no association between pneumococcal susceptibility to Resveratrol and to any currently available antimicrobials tested suggesting different modes of action. However, low selectivity indices (SI) calculated as the ratio between the IC100 in L929 cells and the MIC values were found for meningococci (0.332) and pneumococci (0.125).
Conclusion: Resveratrol inhibited the growth of all N. meningitidis and S. pneumoniae strains causing meningitis in the state of Minas Gerais, Brazil, from 2007 to 2013. Our results, despite the low selectivity indices observed, may warrant further studies to assess the potential of Resveratrol derivates as antimicrobial alternatives to treat meningococcal and pneumococcal infections.
Palabras clave en ingles
Streptococcus pneumoniaNeisseria meningitides
Resveratrol; 3,5,4’-trihydroxylstilbene
Bacterial meningitis
Antibacterials
Natural Compounds
Compartir